Technical Analysis for AMRN - Amarin Corporation plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
24.12 | 4.92% | 1.13 |
AMRN closed up 4.92 percent on Friday, December 13, 2019, on 1.2 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical AMRN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| New 52 Week Closing High | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 4.92% | |
| 180 Bullish Setup | Bullish Swing Setup | 4.92% | |
| NR7 | Range Contraction | 4.92% | |
| Overbought Stochastic | Strength | 4.92% | |
| Golden Cross | Bullish | 5.74% | |
| New Uptrend | Bullish | 5.74% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2019
- Sector: Healthcare
- Industry: Biotechnology
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids. The company lead product comprises Vascepa, a prescription-only omega-3 fatty acid comprising icosapent ethyl as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It also engages in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is headquartered in Dublin, Ireland.
Biopharmaceutical Organic Compounds Nutrition Cardiovascular Diseases Cholesterol Low Density Lipoprotein Lipids Hypertriglyceridemia Saturated Fat
Biopharmaceutical Organic Compounds Nutrition Cardiovascular Diseases Cholesterol Low Density Lipoprotein Lipids Hypertriglyceridemia Saturated Fat
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.67 |
| 52 Week Low | 11.78 |
| Average Volume | 9,486,517 |
| 200-Day Moving Average | 18.26 |
| 50-Day Moving Average | 18.64 |
| 20-Day Moving Average | 22.01 |
| 10-Day Moving Average | 22.58 |
| Average True Range | 1.10 |
| ADX | 26.77 |
| +DI | 34.25 |
| -DI | 14.24 |
| Chandelier Exit (Long, 3 ATRs ) | 21.38 |
| Chandelier Exit (Short, 3 ATRs ) | 22.21 |
| Upper Bollinger Band | 24.32 |
| Lower Bollinger Band | 19.70 |
| Percent B (%b) | 0.96 |
| BandWidth | 20.98 |
| MACD Line | 1.28 |
| MACD Signal Line | 1.23 |
| MACD Histogram | 0.0522 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.88 | ||||
| Resistance 3 (R3) | 25.70 | 24.93 | 25.58 | ||
| Resistance 2 (R2) | 24.93 | 24.49 | 25.02 | 25.48 | |
| Resistance 1 (R1) | 24.53 | 24.21 | 24.73 | 24.71 | 25.39 |
| Pivot Point | 23.76 | 23.76 | 23.87 | 23.85 | 23.76 |
| Support 1 (S1) | 23.36 | 23.32 | 23.56 | 23.54 | 22.85 |
| Support 2 (S2) | 22.59 | 23.04 | 22.68 | 22.76 | |
| Support 3 (S3) | 22.19 | 22.59 | 22.66 | ||
| Support 4 (S4) | 22.37 |
